Psychedelic-assisted therapy may help some people reduce addictive behaviors, but the evidence is still preliminary. Most studies combine substances like psilocybin, LSD, or MDMA with psychotherapy in clinical settings.
Research reports are mixed but encouraging: a randomized trial found psilocybin plus therapy reduced heavy drinking days in alcohol use disorder compared with an active placebo; small pilot work in smoking cessation showed high quit rates without a control group; older LSD studies suggested short-term benefits; and tiny open-label MDMA studies in alcohol use disorder showed reductions in use. These findings are limited by small samples, blinding challenges, and highly selected participants, so they should be interpreted with caution.
Safety in trials depends on careful screening and professional support. Mild effects like headache, nausea, anxiety, and temporary increases in blood pressure and heart rate are relatively common. People with a personal or family history of psychosis or bipolar disorder are typically excluded, and some medications, such as lithium or MAO inhibitors, can increase risks. I cannot verify claims about supplement combinations.
In practice, some clients report strong shifts in craving and motivation after guided sessions, as described in this client story. These are personal experiences, not proof. For now, psychedelic therapy is best seen as a possible adjunct within a broader, professionally supported treatment plan while larger, long-term studies continue.
Approach the topic with cautious optimism and qualified guidance.